KR950704319A - 부신피질자극호르몬-방출 인자(crf) 길항제로서의 피라졸로피리미딘(pyrazolopyrimidines as crf antagonists) - Google Patents

부신피질자극호르몬-방출 인자(crf) 길항제로서의 피라졸로피리미딘(pyrazolopyrimidines as crf antagonists)

Info

Publication number
KR950704319A
KR950704319A KR1019950702452A KR19950702452A KR950704319A KR 950704319 A KR950704319 A KR 950704319A KR 1019950702452 A KR1019950702452 A KR 1019950702452A KR 19950702452 A KR19950702452 A KR 19950702452A KR 950704319 A KR950704319 A KR 950704319A
Authority
KR
South Korea
Prior art keywords
crf
pyrazolopyrimidines
pyrazolopyrimidine
antagonist
stimulating hormone
Prior art date
Application number
KR1019950702452A
Other languages
English (en)
Other versions
KR0167395B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950704319A publication Critical patent/KR950704319A/ko
Application granted granted Critical
Publication of KR0167395B1 publication Critical patent/KR0167395B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1019950702452A 1992-12-17 1993-11-26 부신피질자극호르몬-방출인자 길항제로서의 피라졸로피리미딘 KR0167395B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99222992A 1992-12-17 1992-12-17
US7/992,229 1992-12-17
PCT/US1993/011333 WO1994013677A1 (en) 1992-12-17 1993-11-26 Pyrazolopyrimidines as crf antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019980704894A Division KR100225720B1 (ko) 1992-12-17 1993-11-26 부신피질자극호르몬-방출 인자 길항제로서의 피라졸로피리미딘을 포함하는 약학 조성물

Publications (2)

Publication Number Publication Date
KR950704319A true KR950704319A (ko) 1995-11-17
KR0167395B1 KR0167395B1 (ko) 1999-01-15

Family

ID=25538069

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019980704894A KR100225720B1 (ko) 1992-12-17 1993-11-26 부신피질자극호르몬-방출 인자 길항제로서의 피라졸로피리미딘을 포함하는 약학 조성물
KR1019950702452A KR0167395B1 (ko) 1992-12-17 1993-11-26 부신피질자극호르몬-방출인자 길항제로서의 피라졸로피리미딘

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1019980704894A KR100225720B1 (ko) 1992-12-17 1993-11-26 부신피질자극호르몬-방출 인자 길항제로서의 피라졸로피리미딘을 포함하는 약학 조성물

Country Status (27)

Country Link
US (1) US6218397B1 (ko)
EP (1) EP0674642B1 (ko)
JP (1) JP2862375B2 (ko)
KR (2) KR100225720B1 (ko)
CN (1) CN1034175C (ko)
AT (1) ATE195738T1 (ko)
AU (1) AU680226B2 (ko)
BR (1) BR9307648A (ko)
CA (1) CA2150709C (ko)
CZ (1) CZ287319B6 (ko)
DE (1) DE69329296T2 (ko)
DK (1) DK0674642T3 (ko)
EG (1) EG20273A (ko)
ES (1) ES2150482T3 (ko)
FI (1) FI105920B (ko)
GR (1) GR3034507T3 (ko)
HU (1) HU221507B (ko)
IL (1) IL107944A (ko)
MY (1) MY115300A (ko)
NO (1) NO305437B1 (ko)
NZ (1) NZ259114A (ko)
PL (1) PL177028B1 (ko)
PT (1) PT674642E (ko)
RU (1) RU2124016C1 (ko)
TW (2) TW444018B (ko)
WO (1) WO1994013677A1 (ko)
ZA (1) ZA939405B (ko)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
KR960704855A (ko) 1993-10-12 1996-10-09 돈 엠. 커. 1n-알킬-n-아릴피리미딘아민 및 이들의 유도체 (1n-alkyl-n-arylpyrimidinamines and derivatives thereof)
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JP3004728B2 (ja) * 1994-04-29 2000-01-31 ファイザー インク． 神経伝達物質放出増強薬としての新規な非環式および環式アミド類
FR2719587B1 (fr) * 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
CA2192820C (en) 1994-06-16 2000-11-28 Yuhpyng L. Chen Pyrazolo and pyrrolopyridines
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
US5747495A (en) * 1995-08-22 1998-05-05 Hiroshi Maeda Method for treating hypertension using pyrazolopyrimidine derivatives
DK0778277T3 (da) * 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
US6255310B1 (en) * 1996-02-07 2001-07-03 Neurocrine Biosciences Inc. Thiophenopyrimidines
DE69736513T2 (de) * 1996-02-07 2007-04-05 Neurocrine Biosciences, Inc., San Diego Pyrazolopyrimidine als crf rezeptor-antagonisten
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
NZ331647A (en) * 1996-03-26 2000-03-27 Du Pont Pharm Co Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
EP0915093B1 (en) * 1996-06-06 2002-11-27 Otsuka Pharmaceutical Factory, Inc. Amide derivatives
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
EP0920429B1 (en) * 1996-08-06 2003-02-19 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
US5861398A (en) * 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6159980A (en) * 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
JP2001511813A (ja) * 1997-02-18 2001-08-14 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
SE9701398D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
DE69807085D1 (de) * 1997-09-02 2002-09-12 Bristol Myers Squibb Pharma Co Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
US6613777B1 (en) 1998-03-06 2003-09-02 Chen Chen CRF antagonistic pyrazolo[4,3-b]pyridines
CA2326319A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO2000027850A2 (en) * 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
CN1217945C (zh) * 1998-11-12 2005-09-07 纽罗克里恩生物科学有限公司 Crf受体拮抗剂以及与其有关的方法
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6409988B1 (en) 1999-07-01 2002-06-25 3-Dimensional Pharmaceuticals, Inc. Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands
US6506784B1 (en) 1999-07-01 2003-01-14 3-Dimensional Pharmaceuticals, Inc. Use of 1,3-substituted pyrazol-5-yl sulfonates as pesticides
AU6116800A (en) 1999-07-22 2001-02-13 3-Dimensional Pharmaceuticals, Inc. 1-aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
JP2003510327A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション 特定のアルキレンジアミンで置換された複素環
US6545033B1 (en) 1999-10-06 2003-04-08 3-Dimensional Pharmaceuticals, Inc. Fused 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles, the synthesis thereof and the use thereof as pesticides
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US7605175B2 (en) 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
CA2440553C (en) 2001-03-13 2010-06-08 Paul J. Gilligan 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
RU2308457C2 (ru) 2001-04-27 2007-10-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Пиразоло [1, 5-а] пиридины и содержащие их лекарственные средства
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE10219435A1 (de) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI259083B (en) * 2002-05-24 2006-08-01 Nat Health Research Institutes Anti-enterovirus compounds
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
NZ538860A (en) 2002-10-22 2006-07-28 Eisai Co Ltd 7-Phenyl pyrazolopyridine compounds
KR20050085636A (ko) 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
WO2004092139A2 (en) 2003-04-07 2004-10-28 Gpc Biotech, Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AR045697A1 (es) * 2003-07-14 2005-11-09 Arena Pharm Inc Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005028480A2 (en) * 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
GB0326168D0 (en) * 2003-11-10 2003-12-17 Arrow Therapeutics Ltd Chemical compounds
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
AU2004309415B2 (en) 2003-12-23 2010-08-26 Agennix Usa Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
MXPA06009296A (es) * 2004-02-17 2007-01-26 Transoral Pharmaceuticals Inc Composiciones para suministro de agentes hipnoticos a traves de la mucosa oral y sus metodos de uso.
EP1715853A4 (en) * 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF
US20080287405A1 (en) * 2004-05-14 2008-11-20 Thannickal Victor J Compositions and Methods Relating to Protein Kinase Inhibitors
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
PE20061319A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
GT200600164A (es) * 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
TW200719886A (en) * 2005-04-22 2007-06-01 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
KR20130042041A (ko) * 2005-05-25 2013-04-25 트랜스셉트 파마슈티칼스, 인코포레이티드 야반 불면증을 치료하기 위한 고체 조성물 및 방법
EP1903045A1 (en) * 2005-05-27 2008-03-26 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine derivative
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
CA2611979A1 (en) * 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles
EP1926734A1 (en) 2005-08-22 2008-06-04 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
EA019961B1 (ru) 2006-04-04 2014-07-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы
CA2651898A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
DE102006029074A1 (de) 2006-06-22 2007-12-27 Friedrich-Schiller-Universität Jena 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2526933B1 (en) * 2006-09-22 2015-02-25 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
EP2219649A2 (en) * 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
UA119314C2 (uk) 2008-01-04 2019-06-10 Інтеллікіне Ллк Спосіб отримання похідних ізохінолінону (варіанти)
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2716080C (en) 2008-02-20 2016-12-13 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US8431603B2 (en) 2008-04-15 2013-04-30 Eisai R&D Management Co., Ltd. 3-phenylpyrazolo[5,1-b]thiazole compounds
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
EP2331551B1 (en) 2008-08-26 2016-06-29 Evotec International GmbH Thienopyrimidines for pharmaceutical compositions
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
AU2009305669A1 (en) * 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8853193B2 (en) 2010-02-26 2014-10-07 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
BR112012021364A2 (pt) 2010-02-26 2016-10-25 Boehringer Ingelheim Int "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
SG2014009492A (en) * 2011-08-11 2014-09-26 Intellikine Llc Kinase inhibitor polymorphs
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
HUE059217T2 (hu) * 2011-10-14 2022-10-28 Scandion Oncology As 4-Amino-3-fenil-amino-6-fenil-pirazolo[3,4-d]pirimidin származékok vírusfertõzések, különösen pikornavírus fertõzések kezelésére
DE102012004736A1 (de) 2011-10-20 2013-04-25 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidin-Derivate und deren Verwendung als antivirale Wirkstoffe
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR20150061651A (ko) 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI657085B (zh) 2013-10-04 2019-04-21 英菲尼提製藥股份有限公司 雜環化合物及其用途
ES2913486T3 (es) 2014-03-19 2022-06-02 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para la utilización en el tratamiento de trastornos mediados por PI3K-gamma
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6895378B2 (ja) 2015-01-06 2021-06-30 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
WO2018081451A1 (en) * 2016-10-26 2018-05-03 Indiana University Research And Technology Corporation Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment
WO2019169113A1 (en) * 2018-03-02 2019-09-06 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis
CN110734439A (zh) * 2019-11-07 2020-01-31 中国药科大学 一种母核为吡唑并[3,4-d]嘧啶类化合物及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965643A (en) 1960-12-20 Derivatives of pyrazolo
US3551428A (en) 1956-02-10 1970-12-29 Ciba Geigy Corp New 1- (or 2-) substituted 4-mercapto-pyrazolo(3,4-d)pyrimidines
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
FR1311787A (fr) * 1961-05-10 1962-12-14 Ciba Geigy Procédé de préparation de 4-mercapto-pyrazolo [3, 4-d] pyrimidines
FR2073274A1 (en) * 1969-12-15 1971-10-01 Sapchim Fournier Cimag Sa 4-mercapto-pyrazolo(3,4-d)-pyrimidines prepn
DE2430454A1 (de) * 1974-06-25 1976-01-15 Thomae Gmbh Dr K Neue pyrazolo eckige klammer auf 3,4d eckige klammer zu pyrimidine
US4139705A (en) * 1977-05-20 1979-02-13 The Dow Chemical Company Pyrazolopyrimidines
JPS58208283A (ja) 1982-05-28 1983-12-03 Shigeji Ueda フルフリ−ルアルコ−ルを原料とし時日の変化を伴つても全然変色のない溶剤の製造法
US4426384A (en) 1982-08-05 1984-01-17 John R. A. Simoons Treatment of rheumatoid arthritis and related diseases
IT1154024B (it) 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
US5153352A (en) 1988-10-25 1992-10-06 Bristol-Myers Squibb Company Process for preparation of intermediates of carbocyclic nucleoside analogs
US5391739A (en) * 1989-03-29 1995-02-21 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
CA2100863A1 (en) 1991-01-23 1992-07-24 David A. Bullough Adenosine kinase inhibitors
AU665184B2 (en) * 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors

Also Published As

Publication number Publication date
TW370529B (en) 1999-09-21
NZ259114A (en) 1997-03-24
CA2150709C (en) 1999-03-16
WO1994013677A1 (en) 1994-06-23
FI105920B (fi) 2000-10-31
AU5728194A (en) 1994-07-04
HU9303613D0 (en) 1994-04-28
AU680226B2 (en) 1997-07-24
GR3034507T3 (en) 2000-12-29
TW444018B (en) 2001-07-01
JP2862375B2 (ja) 1999-03-03
IL107944A0 (en) 1994-04-12
EG20273A (en) 1998-05-31
PL177028B1 (pl) 1999-09-30
CZ158695A3 (en) 1995-11-15
KR100225720B1 (ko) 1999-10-15
EP0674642A1 (en) 1995-10-04
US6218397B1 (en) 2001-04-17
CN1034175C (zh) 1997-03-05
NO952399D0 (no) 1995-06-16
JPH07509728A (ja) 1995-10-26
CZ287319B6 (en) 2000-10-11
DK0674642T3 (da) 2000-09-18
ES2150482T3 (es) 2000-12-01
FI935675A (fi) 1994-06-18
DE69329296D1 (de) 2000-09-28
HU221507B (en) 2002-10-28
PT674642E (pt) 2001-01-31
BR9307648A (pt) 1999-05-25
RU2124016C1 (ru) 1998-12-27
PL309359A1 (en) 1995-10-02
KR0167395B1 (ko) 1999-01-15
ZA939405B (en) 1995-06-15
NO305437B1 (no) 1999-05-31
CA2150709A1 (en) 1994-06-23
IL107944A (en) 2000-12-06
DE69329296T2 (de) 2000-12-28
ATE195738T1 (de) 2000-09-15
EP0674642B1 (en) 2000-08-23
HUT70426A (en) 1995-10-30
MY115300A (en) 2003-05-31
CN1094048A (zh) 1994-10-26
NO952399L (no) 1995-08-16
FI935675A0 (fi) 1993-12-16

Similar Documents

Publication Publication Date Title
KR950704319A (ko) 부신피질자극호르몬-방출 인자(crf) 길항제로서의 피라졸로피리미딘(pyrazolopyrimidines as crf antagonists)
GR3034969T3 (en) N-(aroyl)glycine hydroxamic acid derivatives and related compounds
DK295286A (da) (4-piperidinylmethyl og -hetero)puriner
HU9501738D0 (en) Methods for administering crf antagonists
WO2003022216A3 (en) Biaryl substituted purine derivatives as potent antiproliferative agents
BR9812492A (pt) Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
DE69131759D1 (de) An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one
MX9800483A (es) Derivados de piperazina y su uso como antagonistas de 5-ht1a.
DE69106425T2 (de) Sulfonylamin substituierte bizyklische Hydroxansäurederivate.
DE10299023I2 (de) Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
EE03045B1 (et) Angiotensiin II retseptorite antagonistide pürasolopürimidiinide derivaadid, nende valmistamise meetod ja ravimvormid
TH13960EX (th) สารละลายโซมาโตโพรพินที่เข้ากันได้ในทางชีววิทยา
ITMI921151A1 (it) Composti terapeuticamente attivi, particolarmente ad attivita' nootropica e procedimento per la loro preparazione
TH13016EX (th) สารประกอบชนิดใหม่ซึ่งแสดงฤทธิ์ในการรักษาโรค

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030718

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee